MYGN Share Price

Open 20.22 Change Price %
High 20.65 1 Day 0.10 0.49
Low 20.09 1 Week -0.84 -3.97
Close 20.31 1 Month 1.92 10.44
Volume 701207 1 Year -13.78 -40.42
52 Week High 35.35
52 Week Low 15.15
MYGN Important Levels
Resistance 2 20.83
Resistance 1 20.62
Pivot 20.35
Support 1 20.00
Support 2 19.79
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
CLSN 0.23 -93.11%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Myriad Genetics, Inc. (NASDAQ: MYGN)

MYGN Technical Analysis 1.5
As on 26th May 2017 MYGN Share Price closed @ 20.31 and we RECOMMEND Sell for LONG-TERM with Stoploss of 20.54 & Buy for SHORT-TERM with Stoploss of 19.66 we also expect STOCK to react on Following IMPORTANT LEVELS.
MYGN Target for May
1st Target up-side 19.39
2nd Target up-side 20.09
3rd Target up-side 20.79
1st Target down-side 17.39
2nd Target down-side 16.69
3rd Target down-side 15.99
MYGN Other Details
Segment EQ
Market Capital 2496680448.00
Sector Services
Industry Research Services
Offical website http://www.myriad.com
MYGN Address
MYGN
320 Wakara Way
Salt Lake City, UT 84108
United States
Phone: 801-584-3600
Fax: 801-584-3640
MYGN Latest News
Interactive Technical Analysis Chart Myriad Genetics, Inc. ( MYGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Myriad Genetics, Inc.
MYGN Business Profile
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).